EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Lupus Membranous Nephropathy

Claudio Ponticelli, Gabriella Moroni, Alessia Fornoni

Glomerular Diseases · 2021

DOI: 10.1159/000512278 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Glomerular Diseases, 2021. Verfasst von Claudio Ponticelli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology, IRCCS Ospedale Maggiore Policlinico (retired), Milan, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lupus membranous nephropathy (LMN) is a rare disease, usually associated with nephrotic syndrome.

Methods

We reviewed the literature by searching for the following terms on Pubmed.gov: lupus nephritis, membranous nephropathy (MN), lupus membranous nephropathy, nephrotic syndrome, and Class V lupus nephritis.

Results

The histology of LMN at light microscopy is similar to that of primary MN. Cases of MN associated with focal or diffuse proliferation are not considered LMN by the International Society of Nephrology/Renal Pathology Society classification. Immunofluorescence study of LMN shows deposits of all immunoglobulins and complement. Tubulo-reticular structures, extraglomerular deposits, subepithelial, and scanty subendothelial deposits can be seen on electron microscopy. Phospholipase A2 receptor deposits are usually but not necessarily absent in LMN. The pathogenesis is still not completely understood. The inflammatory milieu of lupus may favor the development of autoantigens and intraglomerular assembly of immune complexes. These are more often associated with mesangial or endocapillary hypercellular lesions. Alternatively, autoantibodies may bind autoantigens in the glomerular subepithelium, triggering a signaling cascade leading to LMN. A central role in the development of podocyte injury and proteinuria is played by the components of complement C5b-C9. CKD progression in LMN is slow but may be accelerated by the frequency of renal flares. Persistent nephrotic syndrome and/or the frequent use of corticosteroids may lead to a series of life-threatening complications.

Discussion

Treatment of arterial hypertension, dyslipidemia, and diabetes are of paramount importance. Besides specific therapies of these complications, hydroxychloroquine and vitamin D supplementation are recommended. Immunosuppression should be limited to patients with nephrotic proteinuria. The most frequently used drugs are corticosteroids, calcineurin inhibitors, cyclophosphamide, mycophenolate, and rituximab, alone or combined. Early detection and treatment of renal flares is of paramount importance to prevent CKD progression.

Schlagwörter

Stichwörter der Autor:innen

Chronic kidney diseaseGlomerular diseasesLupus nephritisMembranous nephropathyNephrotic syndrome

Autor:innen und Institutionen

  • Nephrology, IRCCS Ospedale Maggiore Policlinico (retired), Milan, Italy.
  • Nephrology Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Milano, Milan, Italy.
  • Katz Family Division of Nephrology and Hypertension and Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miami, Florida, USA.

Zitieren

APA

Ponticelli, C., Moroni, G., & Fornoni, A. (2021). Lupus Membranous Nephropathy. Glomerular Diseases. https://doi.org/10.1159/000512278

Vancouver

Ponticelli C, Moroni G, Fornoni A. Lupus Membranous Nephropathy. Glomerular Diseases. 2021. doi:10.1159/000512278

BibTeX
@article{Ponticelli2021,
  author = {Ponticelli, Claudio and Moroni, Gabriella and Fornoni, Alessia},
  title = {Lupus Membranous Nephropathy},
  journal = {Glomerular Diseases},
  year = {2021},
  doi = {10.1159/000512278}
}
Kostenlos starten →